Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies.

When healthcare met politics with time running out: 3 new developments
The director of the National Institutes of Health and his principal deputy are touting their success at ‘curing’ the agency of its self-inflicted DEI disability.
FDA approves new nasal spray for patients with abnormal heart rhythms
Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.
American College of Radiology criticizes prominent study pushing for new approach to breast cancer screening
Published Friday in JAMA, scientists recently explored a risk-based mammography tactic that tailors regular imaging regimens to each individual’s danger of developing the disease.
Dozens of new AI-powered devices make FDA's list of approvals
The list, which was updated during the first week of December, now contains over 1,300 artificial intelligence-enabled medical devices.
FDA to add ‘black box’ warning to COVID vaccines, report says
The label is the most serious warning the agency can place on pharmaceuticals, denoting substances that carry serious health risks that must be weighed against benefits. CNN was the first to report the news, citing two sources familiar with the matter.

When healthcare met politics with time running out: 3 new developments

The director of the National Institutes of Health and his principal deputy are touting their success at ‘curing’ the agency of its self-inflicted DEI disability.

Milestone Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for etripamil, a new nasal spray for adult patients with paroxysmal supraventricular tachycardia (PSVT).

FDA approves new nasal spray for patients with abnormal heart rhythms

Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.

breast cancer mammography screening mammogram scheduling

American College of Radiology criticizes prominent study pushing for new approach to breast cancer screening

Published Friday in JAMA, scientists recently explored a risk-based mammography tactic that tailors regular imaging regimens to each individual’s danger of developing the disease.

artificial intelligence AI heart cardiology

Dozens of new AI-powered devices make FDA's list of approvals

The list, which was updated during the first week of December, now contains over 1,300 artificial intelligence-enabled medical devices.

FDA to add ‘black box’ warning to COVID vaccines, report says

The label is the most serious warning the agency can place on pharmaceuticals, denoting substances that carry serious health risks that must be weighed against benefits. CNN was the first to report the news, citing two sources familiar with the matter.

Noteworthy AI news: Prez Trump vs. state regulators, HHS’s AI strategy 1 week out, imperfect AI, more

State-level regulation of AI: President Trump has turned his thinking into action.

Arnold Seto, MD, MPA, FACC, FSCAI, cath lab director, Long Beach VA Medical Center, professor of medicine at Charles Drew University, Society for Cardiovascular Angiography and Interventions (SCAI) treasurer and chair of the SCAI Advocacy Committee, explains changes in payment policy are making ambulatory surgical centers (ASC) and office based labs (OBL) more attractive to both cardiologists and larger health systems.

More interventional procedures may be coming to an ambulatory surgical center near you

ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike.

New recalls announced for troubled heart devices—FDA previously urged customers to seek alternatives

These most recent recalls focus on a series of maintenance issues. In 2024, the FDA advised customers to transition away from the two devices and find alternative treatment options.